BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
677 results:

  • 1. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
    Bhusare N; Kumar M
    Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Principles in the Management of Glioblastoma.
    Roda D; Veiga P; Melo JB; Carreira IM; Ribeiro IP
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674436
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. LncRNA NDUFA6-DT: A Comprehensive Analysis of a Potential LncRNA Biomarker and Its Regulatory Mechanisms in Gliomas.
    Huang R; Kong Y; Luo Z; Li Q
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674418
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
    Dvorakova K; Skarkova V; Vitovcova B; Soukup J; Vosmikova H; Pleskacova Z; Skarka A; Bartos MC; Krupa P; Kasparova P; Petera J; Rudolf E
    BMC Cancer; 2024 Apr; 24(1):509. PubMed ID: 38654280
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of core genes of craniopharyngioma angiogenesis based on single-cell nuclear transcriptome sequencing.
    Zhang J; Xu L; Ye J; Xu C; Wu B; Wu J; Hong T
    Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):136-141. PubMed ID: 38650143
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
    Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
    CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
    Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
    Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
    Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Regulation of inflammatory response by LINC00346 via miR-25-3p-mediated modulation of the PTEN/pi3k/AKT/NF-κB pathway.
    Kim MJ; Lim SG; Cho DH; Lee JY; Suk K; Lee WH
    Biochem Biophys Res Commun; 2024 May; 709():149828. PubMed ID: 38537596
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. WTAP regulates the production of reactive oxygen species, promotes malignant progression, and is closely related to the tumor microenvironment in glioblastoma.
    Ji Q; Guo Y; Li Z; Zhang X
    Aging (Albany NY); 2024 Mar; 16(6):5601-5617. PubMed ID: 38535989
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets.
    Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474373
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a Combination of Radiotherapy and Immunotherapy in Glioma Patients.
    Zhang T; Zhang Q; He X; Lu Y; Shao A; Sun X; Shao Y
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474320
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Glioblastoma Therapy: Past, Present and Future.
    Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Daurisoline suppress glioma progression by inhibiting autophagy through pi3k/AKT/mTOR pathway and increases TMZ sensitivity.
    Yin HT; Hui-Lu ; Yang JH; Li Q; Li M; Zhao QQ; Wen ZP
    Biochem Pharmacol; 2024 May; 223():116113. PubMed ID: 38460907
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
    Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
    ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
    Ezzati S; Salib S; Balasubramaniam M; Aboud O
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Antiproliferative effect of Potentilla fulgens on glioblastoma cancer cells through downregulation of Akt/mTOR signaling pathway.
    Kandemir SI; Ipek P
    J Cancer Res Ther; 2023 Oct; 19(7):1818-1824. PubMed ID: 38376284
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Tenacissoside H repressed the progression of glioblastoma by inhibiting the pi3k/Akt/mTOR signaling pathway.
    Dong J; Qian Y; Zhang W; Xu J; Wang L; Fan Z; Jia M; Wei L; Yang H; Luo X; Wang Y; Jiang Y; Huang Z; Wang Y
    Eur J Pharmacol; 2024 Apr; 968():176401. PubMed ID: 38331340
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. pi3k/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
    Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD
    J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38319732
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Rapid detection of mutations in CSF-cfTNA with the Genexus Integrated Sequencer.
    Arjuna S; Shah M; Dono A; Nunez-Rubiano L; Pichardo-Rojas PS; Zhu JJ; Riascos RF; Luthra R; Roy-Chowdhuri S; Duose D; Wang DH; Lang FF; Esquenazi Y; Ballester LY
    J Neurooncol; 2024 Jan; 166(1):39-49. PubMed ID: 38160230
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 34.